Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
Maryia ZhdanavaAmanda TeepleDominic PilonAditi ShahGabrielle Caron-LapointeKruti JoshiPublished in: Journal of medical economics (2023)
Nearly half of patients experience access issues with first esketamine nasal spray treatment session. All-cause HRU and healthcare costs trend lower in the 6 months after relative to 6 months before esketamine initiation.
Keyphrases
- major depressive disorder
- healthcare
- end stage renal disease
- bipolar disorder
- ejection fraction
- newly diagnosed
- chronic kidney disease
- health insurance
- liver failure
- combination therapy
- prognostic factors
- peritoneal dialysis
- working memory
- intensive care unit
- metabolic syndrome
- insulin resistance
- replacement therapy